Blood Diagnostic Test for Multiple Sclerosis to be Released in May 2017

A pioneering blood test that speeds up the diagnosis of multiple sclerosis (MS) will be released this year.
 
The IsolateMS blood test works in just 7 days, and has reported an accuracy of 90%, according to Multiple Sclerosis News Today. Current testing methods, such as MRIs, can take significantly longer to reach a diagnosis, since they rely on measuring the progress of neurological damage.
 
With the IsolateMS, physicians can administer the test at the onset of the disease.
 
“The 90% accuracy rate of IsolateMS should give providers and patients a great deal of confidence in their results,” Chase Spurlock, CEO of IQuity, told Multiple Sclerosis News Today. “This test augment existing clinical practice and eliminates the period of uncertainly that can accompany an MS diagnosis. IsolateMS allows patients and providers to begin discussing next steps immediately.”
 
The blood test was developed by the Tennessee-based molecular diagnostics startup IQuity. The company began working on the new IsolateMS blood test in January 2016, after the National Institutes of Health granted the company $2 million in seed funding.
 
The IsolateMS is designed to assess a patients’ RNA levels and gene expression, according to Multiple Sclerosis News Today. Prior research by the company shows that patients with autoimmune diseases exhibit distinct RNA expression patters in the blood that differ from individuals without the disease. These findings suggest that RNA markers could be an efficacious way to diagnose autoimmune diseases.
 
Investigators used machine-learning to create a disease-identifying algorithm with the ability to recognize differentially expressed protein-coding genes and noncoding-genes, Multiple Sclerosis News Today reported.
 
IQIsolate, the company’s suite of algorithms, helps scientists analyze RNA markers obtained from a patient’s blood sample and matches their RNA profiles against healthy and sick patient profiles. The process helps determine if a patient’s gene expression pattern is consistent with a specific disease.
 
IsolateMS expected release date is May 2017.
 


Stay up to date on the latest news in specialty pharmacy by getting Specialty Pharmacy Times in your mailbox or inbox for free!

Click here to sign up for free for the bi-monthly Specialty Pharmacy Times print journal delivered to your address.

Click here to sign up for our email newsletters delivered every Monday, Wednesday, and Friday, in addition to breaking news alerts.

Click here to follow us on Facebook. 

Click here to follow us on Twitter. 

Click here to join our LinkedIn group. 


Most Popular

Related Articles

The phase 3 PARADIGMS clinical trial is the first-ever study designed for children and adolescents aged 10 to 17 years old with relapsing forms of multiple sclerosis.
Patients with multiple sclerosis incur higher costs and experience lower health-related quality of life as their disability increases
Growth in midlife mortality includes conditions such as heart disease, liver cancer, pulmonary disease, obesity, and neurologic disorders.
Company Profile >
Contributors >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Advertise
Careers
Contact Us
Terms & Conditions
Privacy
MJH Associates >
Pharmacy Times
OTCGuide
American Journal of Managed Care
Cure
MD Magazine
ONCLive
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2018
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.
 

$vacMongoViewPlus$